FABP4 and Hepatic steatosis: TT-treated mice exhibited protecting against HFD-induced insulin resistance and ameliorated hepatic steatosis, which may be partially due to a decrease in hepatic mRNA levels of aP2, SREBP1c, and GPAT, reduced cellular TAG synthesis and reduced blood TG.